Ana Cecília de Menezes Galvão

Ana Cecília de Menezes Galvão

Auto-generated profile, based on publicly available information

Ana Cecília de Menezes Galvão

Affiliation Laboratory of Hormone Measurement, Postgraduate Program in Psychobiology and Department of Physiology and Behavior, Federal University of Rio Grande do Norte, Natal, RN, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
NGNicole Leite Galvão-Coelho
Nicole Leite Galvão-Coelho
AGAna Cecília de Menezes Galvão
Ana Cecília de Menezes Galvão
RARaíssa Nóbrega de Almeida
Raíssa Nóbrega de Almeida
FPFernanda Palhano-Fontes
Fernanda Palhano-Fontes
IBIsaac Campos Braga
Isaac Campos Braga
DADraulio Barros de Araujo
Draulio Barros de Araujo
Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients (n = 28) and healthy controls (n = 45). We are evaluating the blood inflammatory biomarkers: C-reactive protein and interleukin 6, as a potential consequence of ayahuasca intake and their correlation with serum cortisol and brain-derived neurotrophic factor levels. Blood samples were collected at pre-treatment and 48 hours after substance ingestion to assess the concentration of inflammatory biomarkers, together with administration of the Montgomery-Åsberg Depression Rating Scale. At pre-treatment, patients showed higher C-reactive protein levels than healthy controls and a significant negative correlation between C-reactive protein and serum cortisol levels was revealed (rho = –0.40, n = 14). C-reactive protein in those patients was not correlated with Montgomery-Åsberg Depression Rating Scale scores. We observed a significant reduction of C-reactive protein levels across time in both patients and controls treated with ayahuasca, but not with placebo. Patients treated with ayahuasca showed a significant correlation (rho = + 0.57) between larger reductions of C-reactive protein and lower depressive symptoms at 48 hours after substance ingestion (Montgomery-Åsberg Depression Rating Scale). No significant result with respect to interleukin 6 and brain-derived neurotrophic factor was found. Furthermore, these biomarkers did not predict the antidepressant response or remission rates observed. These findings enhance the understanding of the biological mechanisms behind the observed antidepressant effects of ayahuasca and encourage further clinical trials in adults with depression.

29 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAna Cecília de Menezes Galvão
Ana Cecília de Menezes Galvão
RARaíssa Nobrega Almeida
Raíssa Nobrega Almeida
GJGeovan Menezes de Sousa Júnior
Geovan Menezes de Sousa Júnior
MLMário André Leocadio-Miguel
Mário André Leocadio-Miguel
FPFernanda Palhano-Fontes
Fernanda Palhano-Fontes
NGNicole Leite Galvão-Coelho
Nicole Leite Galvão-Coelho
Background: Molecular biomarkers are promising tools to be routinely used in clinical psychiatry. Among psychiatric diseases, major depression disorder (MDD) has gotten attention due to its growing prevalence and morbidity. Methods: We tested some peripheral molecular parameters such as serum mature Brain-Derived Neurotrophic Factor (mBDNF), plasma C-Reactive Protein (CRP), serum cortisol (SC), and the salivary Cortisol Awakening Response (CAR), as well as the Pittsburgh sleep quality inventory (PSQI), as part of a multibiomarker panel for potential use in MDD diagnosis and evaluation of disease’s chronicity using regression models, and ROC curve. Results: For diagnosis model, two groups were analyzed: patients in the first episode of major depression (MD: n = 30) and a healthy control (CG: n = 32). None of those diagnosis models tested had greater power than Hamilton Depression Rating Scale-6. For MDD chronicity, a group of patients with treatment-resistant major depression (TRD: n = 28) was tested across the MD group. The best chronicity model (p < 0.05) that discriminated between MD and TRD included four parameters, namely PSQI, CAR, SC, and mBDNF (AUC ROC = 0.99), with 96% of sensitivity and 93% of specificity. Conclusion: These results indicate that changes in specific biomarkers (CAR, SC, mBDNF and PSQI) have potential on the evaluation of MDD chronicity, but not for its diagnosis. Therefore, these findings can contribute for further studies aiming the development of a stronger model to be commercially available and used in psychiatry clinical practice.

1 September 2021 in Journal of Applied Animal Welfare Science
Verified
Journal Article
Closed access
MSMariana de França Santos
Mariana de França Santos
AGAna Cecília de Menezes Galvão
Ana Cecília de Menezes Galvão
FSFlávia Santos Silva
Flávia Santos Silva
ESErick dos Santos Silva
Erick dos Santos Silva
GSGeovan de Sousa
Geovan de Sousa
NGNicole Leite Galvão-Coelho
Nicole Leite Galvão-Coelho
Animal welfare is critical to buffer stress in captive animals and to ensure the reliability of data from studies. The most usual environmental enrichment technique (EE) for social non-human primates is the social enrichment. However, some experimental protocols require keeping individuals isolated, thus demanding other types of EE. We tested in six adult Callithrix jacchus females, single housed for experimental purpose, the stress buffering efficacy of a structural enrichment protocol (SEP) and SEP in combination with a foraging enrichment (FSEP) using fecal cortisol and behaviors to infer stress levels. Both types of EE improved welfare in different ways, while cortisol levels decreased with both EE as compared to the baseline, autogrooming, and piloerection increased after FSEP probably due to the new foods. Therefore, these findings support alternative practices of EE when social animals are living in isolation and reinforce the positive role of structural and food enrichment for decreasing stress markers. It also encourages studies on welfare with females, since its use as an animal model has increased .

31 January 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAna Cecília de Menezes Galvão
Ana Cecília de Menezes Galvão
RARaíssa Nóbrega de Almeida
Raíssa Nóbrega de Almeida
ESErick Allan dos Santos Silva
Erick Allan dos Santos Silva
FFFúlvio Aurélio de Morais Freire
Fúlvio Aurélio de Morais Freire
FPFernanda Palhano-Fontes
Fernanda Palhano-Fontes
NGNicole Leite Galvão-Coelho
Nicole Leite Galvão-Coelho
Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized placebo-controlled trial supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients and in healthy volunteers. Subjects received a single dose of ayahuasca or placebo, and both plasma and awakening salivary cortisol response were measured at baseline (before dosing) and 48h after the dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients (DM), both with respect to healthy controls group (C). Salivary cortisol also was measured during dosing session and we observed a large increased for both C and DM that ingested ayahuasca, than placebo groups. After 48h of the dosing session (D2) with ayahuasca, awakening salivary cortisol response (for both sexes) of treated patients became similar to levels detected in controls. This was not observed in patients that ingested placebo. No changes in plasma cortisol were observed after 48 hours of ayahuasca or placebo ingestion for both groups and sexes. Therefore, these findings point to new evidence of modulation of ayahuasca on salivary cortisol levels, as cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes related to etiology of depression, this modulation could be an important part of the antidepressant effects observed with ayahuasca. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.